Next Article in Journal / Special Issue
Inorganic Phosphate Prevents Erk1/2 and Stat3 Activation and Improves Sensitivity to Doxorubicin of MDA-MB-231 Breast Cancer Cells
Previous Article in Journal
Functionalization of Cyclodextrins with N-Hydroxyphthalimide Moiety: A New Class of Supramolecular Pro-Oxidant Organocatalysts
Previous Article in Special Issue
A Combined Molecular Docking/Dynamics Approach to Probe the Binding Mode of Cancer Drugs with Cytochrome P450 3A4

Anti-Tumor Effects of Bak-Proteoliposomes against Glioblastoma

SyNaBi Laboratory, TIMC IMAG, UMR S5525, UJF/CNRS, Joseph Fourier University, Grenoble Cedex 9 38700, France
Laboratory of Oncology, Istituto Giannina Gaslini, Genoa 16147, Italy
The Rex Laboratory, TIMC IMAG, UMR5525, UJF/CNRS, Joseph Fourier University, CHU-Grenoble, BP217, Grenoble Cedex 9 38043, France
Animal Facility, IRCCS Azienda Ospedaliera Universitaria San Martino-IST, Genoa 16132, Italy
Laboratorio di Trasferimento Genico, IRCCS Azienda Ospedaliera Universitaria San Martino-IST, Genoa 16132, Italy
Author to whom correspondence should be addressed.
These authors contributed equally to this work.
Academic Editor: Didier Astruc
Molecules 2015, 20(9), 15893-15909;
Received: 20 July 2015 / Revised: 21 August 2015 / Accepted: 27 August 2015 / Published: 1 September 2015
(This article belongs to the Collection Nanomedicine)
Despite palliative treatments, glioblastoma (GBM) remains a devastating malignancy with a mean survival of about 15 months after diagnosis. Programmed cell-death is de-regulated in almost all GBM and the re-activation of the mitochondrial apoptotic pathway through exogenous bioactive proteins may represent a powerful therapeutic tool to treat multidrug resistant GBM. We have reported that human Bak protein integrated in Liposomes (LB) was able, in vitro, to activate the mitochondrial apoptotic pathway in colon cancer cells. To evaluate the anti-tumor effects of LB on GBM, MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assays and Western blot analysis were performed on GL26 murine cell line. LB treatment shows a dose-dependent inhibition of cell viability, followed by an up-regulation of Bax and a down-modulation of JNK1 proteins. In GL26-bearing mice, two different routes of administration were tested: intra-tumor and intravenous. Biodistribution, tumor growth and animal survival rates were followed. LB show long-lasting tumor accumulation. Moreover, the intra-tumor administration of LB induces tumor growth delay and total tumor regression in about 40% of treated mice, while the intravenous injection leads to a significant increased life span of mice paralleled by an increased tumor cells apoptosis. Our findings are functional to the design of LB with potentiated therapeutic efficacy for GBM. View Full-Text
Keywords: recombinant membrane protein; Bak; proteoliposomes; glioblastoma recombinant membrane protein; Bak; proteoliposomes; glioblastoma
Show Figures

Figure 1

MDPI and ACS Style

Liguori, L.; Pastorino, F.; Rousset, X.; Alfano, S.; Cortes, S.; Emionite, L.; Daga, A.; Ponzoni, M.; Lenormand, J.-L. Anti-Tumor Effects of Bak-Proteoliposomes against Glioblastoma. Molecules 2015, 20, 15893-15909.

AMA Style

Liguori L, Pastorino F, Rousset X, Alfano S, Cortes S, Emionite L, Daga A, Ponzoni M, Lenormand J-L. Anti-Tumor Effects of Bak-Proteoliposomes against Glioblastoma. Molecules. 2015; 20(9):15893-15909.

Chicago/Turabian Style

Liguori, Lavinia, Fabio Pastorino, Xavier Rousset, Silvia Alfano, Sandra Cortes, Laura Emionite, Antonio Daga, Mirco Ponzoni, and Jean-Luc Lenormand. 2015. "Anti-Tumor Effects of Bak-Proteoliposomes against Glioblastoma" Molecules 20, no. 9: 15893-15909.

Find Other Styles

Article Access Map by Country/Region

Only visits after 24 November 2015 are recorded.
Back to TopTop